Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294682 | 0.83 | ATF4 (0.56) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL21384529 | 0.81 | ATF4 (0.59) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL21384535 | 0.81 | ATF4 (0.59) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20722092 | 0.80 | ATF4 (0.54) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20722058 | 0.79 | ATF4 (0.53) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20722098 | 0.79 | ATF4 (0.53) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22627552 | 0.78 | ATF4 (0.55) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL23358827 | 0.78 | ATF4 (0.52) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL23358950 | 0.77 | ATF4 (0.55) | ATF4 | |
| SCHEMBL22990532 | 0.77 | ATF4 (0.54) | ATF4ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. | 2022-12-29 | — | — | US | disclosed |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885ALDH1A1 4576/4885MEN1 3106/4885 |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885ALDH1A1 4576/4885MEN1 3106/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | ATF4 183/4885ALDH1A1 4400/4885MEN1 3690/4885 |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885ALDH1A1 4576/4885MEN1 3106/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | ATF4 81/4885ALDH1A1 4528/4885MEN1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.